Evidence map›Paper›PMID 40330911›Full record

ArticleKidney medicine2025

Vascular Access Thrombosis Events in Patients With Dialysis-Dependent CKD Treated With Vadadustat or Darbepoetin Alfa: The INNO

Wolfgang C Winkelmayer, Steven K Burke, Glenn M Chertow, Kai-Uwe Eckardt, Wenli Luo, Todd Minga, Mark J Sarnak, Prabir Roy-Chaudhury

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wolfgang C WinkelmayerSection of Nephrology, Baylor College of Medicine, Houston, TX.
Steven K BurkeAkebia Therapeutics Inc, Cambridge, MA.
Glenn M ChertowStanford University School of Medicine, Stanford, CA.
Kai-Uwe EckardtDepartment of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Wenli LuoAkebia Therapeutics Inc, Cambridge, MA.
Todd MingaAkebia Therapeutics Inc, Cambridge, MA.
Mark J SarnakDivision of Nephrology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA.
Prabir Roy-ChaudhuryDivision of Nephrology and Hypertension, University of North Carolina Kidney Center, NC, and WG (Bill) Hefner VA Medical Center, Salisbury, NC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: In the global phase 3 INNO Study Design: Phase 3, global, open-label, randomized, active-controlled clinical trials. Setting & Participants: A total of 3,902 patients who initiated dialysis within the past 16 weeks (incident DD-CKD trial; N = 365) or who had been treated with dialysis for >12 weeks (prevalent DD-CKD trial; N = 3,537). Intervention: Eligible patients randomized 1:1 to vadadustat or darbepoetin alfa. Outcomes: Positively adjudicated VAT events. Results: In the INNO Limitations: Trials were not specifically designed to assess VAT rates; uncertain generalizability to nontrial populations. Conclusions: In this secondary analysis of the INNO

Indexed as

Anemiachronic kidney diseasehemodialysisvadadustatvascular access thrombosis

Identifiers

PMID40330911
PMCPMC12051538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.